Beyfortus safety watch: 3,000 korean kids monitored for RSV protection

NCT ID NCT07200206

Recruiting now Prevention Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks the safety of Beyfortus (Nirsevimab) in up to 3,000 Korean children under 24 months who receive the shot to prevent RSV. Researchers will monitor for side effects and serious events over 180 days. It is a real-world safety check, not a test of how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nirsevimab (Beyfortus), a monoclonal antibody injection
What this could lead to: If successful, this study will confirm that Beyfortus is safe for preventing RSV in Korean children, supporting its widespread use.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove effectiveness. Rare side effects may still emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Nam Seung Woo Pediatric: 4100007
RECRUITING

Hwaseong-si, Gyeonggi-do, 18478, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.